| Document |
Document Title |
|
WO/2013/004377A2 |
The invention relates to enzyme compositions comprising at least a) a cocktail of cellulases from Trichoderma reesei, and b) an enzymatic cocktail from Pycnoporus cinnabarinus comprising a cellobiose dehydrogenase (CDH) or c) a recombina...
|
|
WO/2012/154812A1 |
The present invention is directed to L-proline and citric acid co-crystals of (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)meth
yl)-4- methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-tri
ol, pharmaceutical composition...
|
|
WO/2012/127410A1 |
A method for the synthesis of a compound of formula (1) or a salt thereof, wherein A is a carbohydrate linker which is a lactosyl moiety or which consists of a lactosyl moiety and at least one monosaccharide unit selected from the group ...
|
|
WO/2012/119550A1 |
Provided in the present invention is a compound having a structure as represented by Formula (I) or a pharmaceutically acceptable salt or pro-drug ester thereof: [Formula (I)], where R1 is selected among the straight-chain or branched-ch...
|
|
WO/2012/116196A2 |
The invention provides methods for producing compounds comprising a substitution at the 1'-position of a lactosyl ring. Also provided are compounds having a radionuclide, such as 18F substituted at the 1'-position of a lactosyl ring. Com...
|
|
WO/2012/109996A1 |
Disclosed are an aryl glycoside compound as represented by formula I or formula I', a pharmaceutically acceptable salt thereof, optical isomer thereof or a prodrug thereof. The present invention relates to a method of preparing said aryl...
|
|
WO/2012/097052A2 |
The present invention relates to compounds and methods which may be useful as inhibitors of glycolysis, inhibitors of protein glycosylation, anti-virals, and down-regulators of insulin receptor and IGF- 1 receptor for the treatment or pr...
|
|
WO/2012/091606A1 |
The invention relates to glycan arrays with quantified levels of glycan expression and a method for fabricating thereof. The method comprises quantitatively reacting an ω-aminoalkylglycan with an activated polymer of an acrylic acid der...
|
|
WO/2012/054526A2 |
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory rece...
|
|
WO/2012/047763A2 |
Flavonoid glycosides, such as isoquercitrin, are shown to stimulate the formation of neuritis and neuronal synapses in neurons and neuronal progenitor (stem) cells.
|
|
WO/2012/048202A2 |
The invention is directed to processes for synthesizing bicyclic nucleoside antiviral compounds and for synthesizing the intermediates used in the process. The invention is also directed to novel intermediate compounds useful in the proc...
|
|
WO/2012/037038A1 |
Provided are methods for treating Orthomyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I wherein R2 is halogen. The compounds, compositions, and methods provided particularly ...
|
|
WO/2012/033390A2 |
The present invention relates to a novel compound with thiophene ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comp...
|
|
WO/2012/025857A1 |
The invention relates to the cycloalkyl methoxybenzyl phenyl pyran derivatives as Sodium dependent glucose co transporter (SGLT) inhibitors, particularly SGLT2 and method of treating diseases, conditions and/or disorders inhibited by SGL...
|
|
WO/2012/019496A1 |
Disclosed are C-aryl glucoside derivatives, preparation processes and pharmaceutical uses thereof, especially C-aryl glucoside derivatives represented by general formula (I), pharmaceutical salts or all stereoisomers thereof, their prepa...
|
|
WO/2012/003811A1 |
C-aryl glucosides which are inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), shown as formula I, a pharmaceutical composition and pharmaceutical combination.
|
|
WO/2011/157746A1 |
The present invention relates to the cosmetic use of compounds of formula (I) in which: - S denotes a monosaccharide; the S-CH2D bond represents a bond of anomeric C nature; - D-X denotes a -CH(OH)- or -CO- group; - -A-B- denotes -CH2-CH...
|
|
WO/2011/153953A1 |
Crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2 are disclosed. Pharmaceutical compositions, methods for preparing the crystalline compound, and methods of using the crystalline ...
|
|
WO/2011/153712A1 |
Crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2 are disclosed. Pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline c...
|
|
WO/2011/107494A1 |
The invention relates to aromatic glycoside derivatives of the formula (I), in which the groups have the given meanings, to the physiologically acceptable salts thereof, and to methods for the production thereof. The compounds are suitab...
|
|
WO/2011/095050A1 |
Disclosed are C-glycoside sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors containing saturated 6-member rings shown as following general formula I, preparation methods, compositions containing such compounds and uses thereof ...
|
|
WO/2011/091710A1 |
Disclosed are sodium dependent glucose cotransporter inhibitors II with the phenyl C-glucoside structure, their preparation methods, the pharmaceutical compositions containing them, the uses of treating diabetes and manufacturing a medic...
|
|
WO/2011/079772A1 |
A method for preparation of 2, 5-disubstituted thiophene compound I and its use for the preparation of compound V are disclosed. The said method comprises reacting compound II with compound III in the presence of a sulfur reagent to obta...
|
|
WO/2011/057192A2 |
The invention relates to amphiphilic C-glycoside derivatives, to methods of using them and to processes for synthesizing them. Specifically, the invention relates to novel cyclic and linear enone-glycolipids and cyclic ketone-glycolipids.
|
|
WO/2011/051864A1 |
Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
|
|
WO/2011/048554A2 |
The present invention relates to the cosmetic use of a combination including a lysate of at least one probiotic microorganism of the Bifidobacterium sp. genus having at least one C-glycoside derivative as an active agent that can be used...
|
|
WO/2011/046057A1 |
Provided is a novel and non-natural sialic acid-containing sugar chain compound, which has a binding activity to a viral particle and remains stable even in the presence of sialidase, obtained by using a reaction with the use of a glycos...
|
|
WO/2011/043107A1 |
Disclosed is a method for extracting a compound containing sialic acid from a raw material that is readily available and does not has undergo the contamination by any animal-affecting pathogen (i.e., has high safety), wherein the method ...
|
|
WO/2011/040360A1 |
Disclosed is a method for simply and efficiently separating a sialyllactose material starting with a milk material. Sialyllactose can be concentrated and separated by a simple method comprising deproteinizing a milk material, adjusting t...
|
|
WO/2011/013398A1 |
Disclosed is a compound which has a high affinity for a CD22 molecule in a B cell and can enhance an immune response to thereby exhibit activities including an activity of enhancing the proliferation of B cells and an activity of increas...
|
|
WO/2010/131712A1 |
Disclosed are a therapeutic pharmaceutical agent for diseases associated with the decrease in the function of GNE protein, a food composition, and a food additive. The therapeutic pharmaceutical agent is characterized by comprising a com...
|
|
WO/2010/131745A1 |
Disclosed are: an 18F-labeled azide compound usable in a Huisgen reaction which enables 18F-labeling even though there is only a small amount of an alkyne compound that is the subject substrate, is applicable to PET methods for peptides ...
|
|
WO/2010/128120A1 |
A novel indicator platform comprises a plurality of 1 H-lndol-3-yl indicator compounds that are capable of converting to a signalophore compound in response to an external stimulus. In one class of indicator compounds, the resulting sign...
|
|
WO/2010/128152A1 |
The present invention provides compounds of Formula (IA) wherein A is selected from Formula (II) which have an inhibitory effect on the sodium dependent glucose transporter SGLT and their use in the treatment of diabetes.
|
|
WO/2010/102512A1 |
The present invention discloses C-aryl glucoside derivatives, preparation process and pharmaceutical use thereof, especially C-aryl glucoside derivatives presented by formula (I), pharmaceutical salts and stereoisomers thereof, methods f...
|
|
WO/2010/067010A2 |
The invention relates to derivatives of morphine-6-glucuronide having formula (I) wherein R1 is a 5-membered heteroaromatic group optionally substituted by one or more substituents selected from among halogen atoms and (C1-C4)alkyl, halo...
|
|
WO/2010/067036A1 |
The present invention relates to novel compounds of formula (I) where: X is an –OH or =O grouping; n is an integer between 0 and 5; R’ is H or a C1-C4 alkyl radical, when n ≥ 2, two adjacent –OR’ groupings can together form the...
|
|
WO/2010/067008A2 |
The invention relates to compounds having formula (I) wherein: R1 represents a hydrogen atom or a (C1-C4)alkyl group; R2 represents a hydroxyl group, a thiol group, a (C1-C4)alkyloxy group or a thio(C1-C4)alkyl group; and n is an integer...
|
|
WO/2010/066970A1 |
The invention relates to novel compounds having flavour enhancer properties, to a method for obtaining these novel compounds, and to use of these compounds as flavour enhancers.
|
|
WO/2010/063948A2 |
The present invention relates to novel compound of formula I, where R is a hydrogen atom or a C1–C22 saturated or C2–C22 unsaturated linear alkyl radical, or a C3–C22 saturated or unsaturated branched alkyl radical, said alkyl radi...
|
|
WO/2010/063953A2 |
The present invention relates to novel compounds of formula (I) where R is: a C2–C18 alkyl radical, or a –CHR1 –COOR2 radical, where: R1 is H or a C1–C6 alkyl radical, and R2 is a C1–C6 linear alkyl radical, a C3–C6 cyclic al...
|
|
WO/2010/059958A2 |
Lectins are important class of sugar-binding proteins involved in a variety of biological phenomena. In some aspects, the present invention relates to the process of selection and application of high-fidelity artificial lectin mimics in ...
|
|
WO/2009/093821A9 |
This invention relates to a peptide nucleic acid (PNA) oligomer which is conjugated with one or more linear-type amino acid containing a plurality of alkyleneglycols and to a synthesis method thereof. In addition, this invention relates ...
|
|
WO/2010/052314A2 |
The invention relates to C-glycose compounds of formula (I) where: S’ is a monosaccharide radical or a polysaccharide radical derived from a monosaccharide or polysaccharide S; R is a linear or branched alkyl radical; and Z is an ethyl...
|
|
WO/2010/049451A2 |
The invention relates to C-glycosidic analogues of alpha-galactosylceramids of the general formula (I) having immunostimulating and immunoregulating properties.
|
|
WO/2010/036407A2 |
The invention provides compounds as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds are useful as anti-...
|
|
WO/2010/029302A2 |
Compounds for treating viral infections are disclosed, and in particular sialic acid derivatives that are capable of inhibiting influenza neuramidinases. The present invention also relates to compositions, methods and medical uses that e...
|
|
WO/2010/018834A1 |
Provided is a method for releasing a glycan which can be applied to construction of a system for automatizing glycan analysis, particularly a method for releasing a glycan with which O-linked glycan analysis can be performed. It was ach...
|
|
WO/2010/012153A1 |
Phlorizin derivatives of formula (I), their preparation and their use for manufacture of pharmaceutical compositions. The said compounds exhibit SGLT2 inhibitory activity and can be used to treat metabolic diseases such as diabetes and i...
|
|
WO/2009/154276A1 |
Disclosed is a process for producing a spiroketal derivative through a compound represented by formula (VI) [wherein the variable groups and the variable numbers are as defined in the description] which can be produced from a dihalobenzy...
|
